Here are three things to know.
- The Parkinson’s drug levodopa can cause dyskinesia, or uncontrolled, involuntary movement.
- Gocovri is a once-daily drug intended to control levodopa-induced dyskinesia. The drugs main ingredient, amantadine, has been on the market for several decades as an antiviral drug.
- Adamas Pharmaceuticals expects the drug to be available in the fourth quarter of this year and formally launch in January 2018.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
